Shots:
- Alteogen has granted Biogen exclusive rights to ALT-B4 (berahyaluronidase alfa) to develop & commercialize SC formulations of two biologics, with an option for Biogen to develop a third product
- As per the deal, Alteogen will receive $20M upfront, $10M upon initiation of second product development, along with ~$549M in development, regulatory, & sales milestones for both products, plus net sales-based royalties
- ALT-B4, developed using Hybrozyme tech, is a human recombinant hyaluronidase enzyme that temporarily hydrolyzes hyaluronan in the extracellular matrix. This allows SC administration of drugs which are usually given via IV infusion
Ref: PRnewswire | Image: Alteogen & Biogen | Press Release
Related News: Tesaro (GSK) Licenses Alteogen’s ALT-B4 to Develop & Commercialize SC Formulation of Dostarlimab
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
